Evidence map›Paper›PMID 27838739›Full record

Trial reportClinical research in cardiology : official journal of the German Cardiac Society2017

Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure: insights from the RELAX-AHF study.

Sven Meyer, John R Teerlink, Marco Metra, Piotr Ponikowski, Gad Cotter, Beth A Davison, G Michael Felker, Gerasimos Filippatos, Barry H Greenberg, Tsushung A Hua and 3 more

Registry-linked trialOpen access · hybridAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Clinical research in cardiology : official journal of the German Cardiac Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00520806 (A Phase II/III, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Relaxin in Subjects With Acute Heart Failure), which is not on this map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00520806 phase2 / phase3completednot on this map

A Phase II/III, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Relaxin in Subjects With Acute Heart Failure

TypeinterventionalSponsorCorthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companiesRan2007 to 2012Enrolled1,161ConditionsHeart Failure, CongestiveArmsRelaxin, Placebo
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 22 citations in OpenAlex.

  1. Effects of natriuresis-guided diuretic therapy in men and women with acute heart failure: insights from PUSH-AHF.Clinical research in cardiology : official journal of the German Cardiac Society · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Does rhythm matter in acute heart failure? An insight from the British Society for Heart Failure National Audit.Clinical research in cardiology : official journal of the German Cardiac Society · 2019
    Article
  8. Symptom patterns and clinical outcomes in women versus men with systolic heart failure and depression.Clinical research in cardiology : official journal of the German Cardiac Society · 2019
    Article
  9. Sex differences in risk of incident venous thromboembolism in heart failure patients.Clinical research in cardiology : official journal of the German Cardiac Society · 2019
    Observational
  10. Predictors of survival stratification in patients with wild-type cardiac amyloidosis.Clinical research in cardiology : official journal of the German Cardiac Society · 2018
    Article
  11. Article
  12. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 11 institutions in 7 countries.

Sven MeyerDepartment of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
John R TeerlinkUniversity of California at San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA.
Marco MetraCardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
Piotr PonikowskiMedical University, Clinical Military Hospital, Wroclaw, Poland.
Gad CotterMomentum Research Inc., Durham, NC, USA.
Beth A DavisonMomentum Research Inc., Durham, NC, USA.
G Michael FelkerDuke University School of Medicine, Duke Heart Center, Durham, NC, USA.
Gerasimos FilippatosAthens University Hospital, Attikon, Athens, Greece.
Barry H GreenbergUniversity of California at San Diego, La Jolla, CA, USA.
Tsushung A HuaNovartis Pharmaceuticals Corp., East Hanover, NJ, USA.
Thomas SeverinNovartis Pharma AG, Basel, Switzerland.
Min QianColumbia University Medical Center, New York, NY, USA.
Adriaan A VoorsDepartment of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. a.a.voors@umcg.nl.
Momentum Research · USUniversity Medical Center Groningen · NLColumbia University Irving Medical Center · USDuke University · USNovartis (Switzerland) · CHNovartis (United States) · USSan Francisco VA Medical Center · USUniversity General Hospital Attikon · GRUniversity of Brescia · ITUniversity of California, San Diego · USWroclaw Medical University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsWomen with heart failure are typically older, and more often have hypertension and a preserved left ventricular ejection fraction as compared with men. We sought to analyze if these sex differences influence the course and outcome of acute heart failure. METHODS AND

resultsWe analyzed sex differences in acute heart failure in 1161 patients enrolled in the RELAX-AHF study. The pre-specified study endpoints were used. At baseline, women (436/1161 patients) were older, had a higher left ventricular ejection fraction, a higher rate of hypertension, and were treated differently from men. Early dyspnea improvement (moderate or marked dyspnea improvement measured by Likert scale during the first 24 h) was greater in women. However, dyspnea improvement over the first 5 days (change from baseline in the visual analog scale area under the curve (VAS AUC) to day 5) was similar between men and women. Women reported greater improvements in general wellbeing by Likert, but no such benefits were evident with the VAS score. Multi-variable predictors of moderate or marked dyspnea improvement were female sex (p = 0.0011), lower age (p = 0.0026) and lower diuretic dose (p = 0.0067). The additional efficacy endpoints of RELAX-AHF were similar between men and women and serelaxin was equally effective in men and women.

conclusionsWomen exhibit better earlier dyspnea relief and improvement in general wellbeing compared with men, even adjusted for age and left ventricular ejection fraction. However, in-hospital and post-discharge clinical outcomes were similar between men and women. This trial is registered at ClinicalTrials.gov, NCT00520806.

Indexed as

Acute DiseaseAgedDose-Response Relationship, DrugDouble-Blind MethodDyspneaEuropeFemaleHeart FailureHumansIncidenceInjections, IntravenousLength of StayMalePrognosisRecombinant ProteinsRelaxinRecombinant ProteinsRelaxinserelaxin protein, humanAcute heart failureDyspneaGenderSerelaxinSex

Identifiers

PMID27838739
PMCPMC5360825
OpenAlexW2554316693

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.